Abstract:Background: The somatic mutations that drive acute myeloid leukaemia (AML) are highly heterogenous. Identifying the mutations that drive individual cases can help determine patient prognosis and therapy. For this reason, genetic testing for prognostically important mutations in leukaemic DNA is now routine in many diagnostic laboratories. Also, the analysis of gene-expression profiles from AML RNA can provide additional clinically useful information that cannot be inferred from DNA sequencing. Whilst it is both expensive and impractical to carry out both types of sequencing and analyses, we hypothesised that the two could be combined more cheaply and effectively if the presence of mutations in prognostically important gene mutations could be identified from RNA-seq data. However, computational methodologies for robust detection of the diverse types of somatic mutations found in AML such as substitutions, indels, tandem duplications and translocations, are not currently available. Aims: To develop an stand-alone, lightweight and use-friendly software for the identification of clinically relevant mutations from AML RNA-seq data. Methods: To ensure efficient mapping of RNA-seq reads, we hash-indexed the DNA sequences of target genes using 10-mer sliding windows and implemented the ”seed and extend“ algorithm for read alignment. Point mutations and small indels were detected from reads with imperfect alignments and tandem duplications were detected from reads spanning the duplication junction. Translocations were detected from reads whose ends belonged to preselected fusion partner genes. Results: To benchmark our software we used RNA-seq data from 151 whole-exome/genome-sequenced AML samples studied by The Cancer Genome Atlas Research Network. We show that our software reliably calls clinically important mutations affecting the genes NPM1 (4-nt insertion), FLT3 (substitutions and internal tandem duplications, ITD), MLL partial tandem duplications (PTD), as well as substitutions in CEBPA, IDH1/2, TP53 and RUNX1. Furthermore, we identified gene fusions including PML-RARA, MYH11-CBFB, RUNX1-RUNX1T1, BCR-ABL1 and NUP98-NSD1. Our software is fast and memory efficient and is able to identify the above mutations in less than 20 minutes starting with RNA-seq FastQ files of 100 million 50 bp paired-end reads, using a standard modern laptop computer. In addition, the software operates through a graphical user interface making it accessible to users without programming knowledge. Summary/Conclusion: We demonstrated that clinically important somatic mutations that drives AML can be reliably detected from RNA-seq data alone using our software. As our approach can be readily combined with conventional gene expression analyses of the same RNA-seq dataset, it can be used to generate data with enhanced clinical utility that can improve prognostication and guide patient treatment. As RNA sequencing is a straightforward procedure, our approach can readily enter clinical laboratories, where it can significantly reduce experimental costs and accelerate diagnostic work-ups.

ALRIGMR: Adaptive logistic regression via integrating gene mutation and RNA-seq for liver cancer diagnosis

Optimizing Prognostic Predictions in Liver Cancer with Machine Learning and Survival Analysis

WGCNA combined with machine learning to find potential biomarkers of liver cancer

Identifying novel transcript biomarkers for hepatocellular carcinoma (HCC) using RNA-Seq datasets and machine learning

Detecting Robust Gene Signature Through Integrated Analysis of Multiple Types of High-Throughput Data in Liver Cancer

Unveiling efferocytosis-related signatures through the integration of single-cell analysis and machine learning: a predictive framework for prognosis and immunotherapy response in hepatocellular carcinoma

Early Diagnosis of Hepatocellular Carcinoma Using Machine Learning Method

Discovering the molecular differences between right- and left-sided colon cancer using machine learning methods

Construction of a lipid metabolism-related risk model for hepatocellular carcinoma by single cell and machine learning analysis

Identification of important long non-coding RNAs and highly recurrent aberrant alternative splicing events in hepatocellular carcinoma through integrative analysis of multiple RNA-Seq datasets

Prioritizing cancer lncRNA modulators via integrated lncRNA-mRNA network and somatic mutation data

Identification and development of TP53 mutation-associated Long non-coding RNAs signature for optimized prognosis assessment and treatment selection in hepatocellular carcinoma

Comprehensive Molecular Analyses of a Six-Gene Signature for Predicting Late Recurrence of Hepatocellular Carcinoma

Identifying Apoptosis-Related Transcriptomic Aberrations and Revealing Clinical Relevance as Diagnostic and Prognostic Biomarker in Hepatocellular Carcinoma

Comprehensive molecular analyses of a 7-m6A-related lncRNAs signature for prognosis, tumor immunity and therapeutic effect in patients with hepatocellular carcinoma

Prognostic prediction using a gene signature developed based on exhausted T cells for liver cancer patients

Establishment of diagnostic model and identification of diagnostic markers between liver cancer and cirrhosis based on multi-chip and machine learning

PS1040 DETECTION OF MRD MAY PREDICT THE OUTCOME OF PATIENTS WITH ACUTE MYELOID LEUKEMIA WITH BIALLELIC CEBPA MUTATIONS

Coupled scRNA-seq and Bulk-seq reveal the role of HMMR in hepatocellular carcinoma

Integrative Analysis of Long Extracellular RNAs Reveals a Detection Panel of Noncoding RNAs for Liver Cancer.

Identification and validation of immune-related gene signature models for predicting prognosis and immunotherapy response in hepatocellular carcinoma